Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Siddique Abbasi"'
Autor:
Winnie Sohn, Jan Wahlstrom, Marintan Spring, Hanze Zhang, Siddique Abbasi, Stephen Flach, Sandeep Dutta, Priyanka Kulkarni, Ashit Trivedi, Edward Lee, Pegah Jafarinasabian
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with h
Autor:
Sandeep Dutta, Bianca Terminello, Pegah Jafarinasabian, Winnie Sohn, Siddique Abbasi, Hanze Zhang, Edward Lee, Ashit Trivedi, Stephen Flach
Publikováno v:
Clinical Pharmacology in Drug Development. 11:129-133
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure (HF) with reduced ejection fraction. OM is administered as a 25-, 37.5-, or 50-mg modified-release formulation in patients with HF. Proton p
Autor:
Hanze Zhang, Pegah Jafarinasabian, Shauna Hutton, Siddique Abbasi, Mia Mackowski, Rajneet K. Oberoi, Stephen Flach, Edward Lee, Sandeep Dutta, Ashit Trivedi
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1442-1451
Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM is primarily eliminated via metabolism mediated by multiple cytochrome P450 enzymes. This
Autor:
Hanze Zhang, Edward Lee, Marintan Spring, Siddique Abbasi, Pegah Jafarinasabian, Ashit Trivedi, Rajneet K. Oberoi, Stephen Flach, Sandeep Dutta
Publikováno v:
Clinical Drug Investigation. 41:647-652
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure with reduced ejection fraction. The objective of this study was to evaluate the potential for OM to affect the pharmacokinetics of metformin
Autor:
Siddique Abbasi, Suvasini Lakshmanan, Matthew D. Jankowich, Gaurav Choudhary, Alan R. Morrison, Wen-Chih Wu
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Pulmonary Circulation
Pulmonary Circulation
Background Adiponectin is a polypeptide hormone related to obesity, and a known modulator of pulmonary vascular remodeling. Association between plasma adiponectin levels and pulmonary hypertension (PH) has not been studied in African Americans (AAs)
Autor:
Edward Lee, Sandeep Dutta, Siddique Abbasi, Mia Mackowski, Makoto Aoki, Ashit Trivedi, Fady I. Malik, Shauna Hutton
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 46(6)
Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The pharmacokinetics of single and multiple doses of OM were investigated in healthy Japanese subjects in two clinical studies. Study 1 (n = 3
Autor:
Edward Lee, Sandeep Dutta, Winnie Sohn, Cheng-Pang Hsu, Stephen Flach, Pegah Jafarinasabian, Siddique Abbasi, Hanze Zhang, Shauna Hutton, Ashit Trivedi
Publikováno v:
Clinical pharmacology in drug development. 11(3)
Omecamtiv mecarbil (OM), a novel cardiac myosin activator, is being evaluated for the treatment of heart failure with reduced ejection fraction. In vitro studies demonstrate OM as a substrate and inhibitor of P-glycoprotein (P-gp), which can result i
Autor:
Hanze Zhang, Rajneet K. Oberoi, Stephen Flach, Siddique Abbasi, Sandeep Dutta, Ashit Trivedi, Pegah Jafarinasabian, Edward Lee
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Omecamtiv mecarbil is a novel selective cardiac myosin activator (myotrope) under investigation for the treatment of heart failure with reduced ejection fraction. The objective of this clinical study was to estimate the effec
Autor:
Eri Watanabe, Otavio R. Coelho-Filho, Yuna L. Choi, Ayaz Aghayev, Carlos H Rassi, Siddique Abbasi, Ethan Rowin, Raymond Y. Kwong, François-Pierre Mongeon, Kathleen Cheng, Michael M. Givertz, Michael Jerosch-Herold, Tomas G. Neilan, Tomas Vita, Hoshang Farhad, Ron Blankstein, Christoph Gräni, Michael L. Steigner, Kyoichi Kaneko
Publikováno v:
JACC: Cardiovascular Imaging. 12:1659-1669
Objectives: In patients with nonischemic dilated cardiomyopathy (NIDCM), native T1, partition coefficient (λGd), and extracellular volume fraction (ECV) mapping may offer prognostic values ...
Autor:
Tor Biering-Sørensen, M. Lund, Eileen O'Meara, Stephen B. Heitner, Jindrich Spinar, Marco Metra, Shin-ichi Momomura, Michael Böhm, Diana Bonderman, Piotr Ponikowski, Jose H. Flores-Arredondo, James C. Fang, Siddique Abbasi, Scott D. Solomon, John R. Teerlink, Galactic-Hf Investigators, Fady I. Malik, Brian Claggett, Stuart Kupfer, John J.V. McMurray, Rafael Diaz, David E Lanfear, G. Michael Felker
Publikováno v:
GALACTIC HF Investigators 2021, ' Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF ', American College of Cardiology. Symposia, vol. 78, no. 2, pp. 97-108 . https://doi.org/10.1016/j.jacc.2021.04.065
Background: \ud In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, omecamtiv mecarbil, significantly reduced the primary composite endpoint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b84d6e24d7eb47364ec58d9abf4b90b0
https://curis.ku.dk/portal/da/publications/effect-of-ejection-fraction-on-clinical-outcomes-in-patients-treated-with-omecamtiv-mecarbil-in-galactichf(0f84e619-bf1b-467d-9304-c8908158c15d).html
https://curis.ku.dk/portal/da/publications/effect-of-ejection-fraction-on-clinical-outcomes-in-patients-treated-with-omecamtiv-mecarbil-in-galactichf(0f84e619-bf1b-467d-9304-c8908158c15d).html